Safety of lurasidone for the treatment of adult patients with schizophrenia: Relationship between timing of administration and risk of adverse events

Katsuhiko HAGI

Presentation information

[CNP] Poster Session

CNP » [CNP] Poster Session

[CNP_P9] Poster Session 9

Fri. Oct 11, 2019 1:40 PM - 3:10 PM Poster Hall (Multi-purpose Hall)

座長：嶽北　佳輝（関西医科大学精神神経科学教室）

1:56 PM - 2:04 PM

[CNP-P9-3] Safety of lurasidone for the treatment of adult patients with schizophrenia: Relationship between timing of administration and risk of adverse events

^○Katsuhiko HAGI¹, Tadashi NOSAKA¹, Andrei PIKALOV² (1. Sumitomo Dainippon Pharma Co., Ltd., 2. Sunovion Pharmaceuticals, Inc.)

Abstract password authentication.
Password to browse/download the abstracts has been sent to pre-registrants by email and printed on name badge. It is also indicated in the abstract booklet.